Serious Revenues fall, at the company in the financial fourth quarter of 2022

In the financial interval ending December 31 2022 SCKT reported soft top and bottom-line, where reached balanced books and revenue by -15.427 % year on year. Revenue were to $5.17 millions in contrast to $6.11 millions eps at $0.00 relative to $0.09 in the financial interval ending December 31 2021.

Socket Mobile Inc stock quotes, charts, profile

Socket Mobile Inc Revenue elevation Rates

The company caused some great news for the shareholders, presenting a significant improvement in fourth quarter of 2022 earnings season with operating loss of $-8.322 millions

While the earnings cycle of fiscal October to December 31 2022 period continues, countless corporations have reported the respective numbers. In the thick of it, are many entities in the Medical Equipment & Supplies industry. As well as, now, BTTX published operating loss of $-8.322 millions, for the fourth quarter of 2022 earnings season.

Better Therapeutics Inc Suppliers

Better Therapeutics Inc improvement Rates, Profitability, PE

For the fourth quarter of 2022 earnings season APVO decreased a loss per share of $-0.84 per share compare to $-1.28 a year prior and earnings per share improved from $-1.50 per share from the previous reporting season.

Revenues remained unaltered to $0.00 millions from $3.67 millions in the comparable reporting season a year prior and sequentially Revenues surged from $0.00 millions.

Aptevo Therapeutics Inc Competitors, Market Share

Aptevo Therapeutics Inc Income Statement, Balance sheets, Cash Flow Statement

Shifting our awareness to the financial span closing Dec 31 2022 CADL Losses have widen at $-0.15 per share, relative to the earnings of $1.54 per share a year ago reporting period, In the previous reporting period CADL realized $-0.30 per share.

Candel Therapeutics Inc Customers

Candel Therapeutics Inc Suppliers

Very noticeable Contraction in Revenues at NONE in the fiscal fourth quarter of 2022

For the financial time-frame closing December 31 2022 NONE bottom-line turned positive of $0.01 per share compare to $-0.14 a year ago and earnings per share dropped by -99.63 % from $1.64 per share from the prior reporting period.

Revenues faded by -37.649 % to $0.19 millions from $0.31 millions in the same reporting period a year ago and sequentially Revenue Tumbled by -49.218 % from $0.38 millions.

Aei Income And Growth Fund Xxi Limited Partnership Competitors, Market Share

Aei Income And Growth Fund Xxi Limited Partnership Suppliers

Deficit bigger than a year before at the Creative Media And Community Trust Corporation over the fourth quarter of 2022

For the fourth quarter of 2022 CMCT Deficit has expanded of $-0.39 per share compare to $-0.38 a year before and earnings per share improved from $-0.50 per share from the prior financial reporting period.

Revenue grew softly by 2.957 % to $25.87 millions from $25.13 millions in the comparable financial reporting period a year before and sequentially Revenues increased by 4.084 % from $24.85 millions.

Creative Media And Community Trust Corporation Customers

Creative Media And Community Trust Corporation Revenue elevation Rates

Profitability not reached inspite of notable Revenues at in the fourth quarter of 2022

For the fourth quarter of 2022 Aspira Women S Health Inc lost money of $-0.04 per share compare to $-0.08 a year prior and from $-0.04 per share from the prior financial reporting period.

Revenues grew extensively by 16.316 % to $2.15 millions from $1.85 millions in the same financial reporting period a year prior and sequentially Revenues increased by 3.909 % from $2.07 millions.

Aspira Women S Health Inc Competitors, Market Share

Aspira Women S Health Inc Income Statement, Balance sheets, Cash Flow Statement

The Regional Banks company reported marginal reduction in their top-line, during the October to December 31 2022 time-frame

For the most recent fiscal period company income per share plummeted by -44.5 % of $0.55 per share compare to $0.99 a year before and profit plummeted by -55.19 % from $1.22 per share from the previous financial reporting period.

Revenues depreciated by -6.343 % to $8.80 millions from $9.40 millions in the corresponding financial reporting period a year before and sequentially Revenues fell by -26.514 % from $11.98 millions.

Quaint Oak Bancorp Inc stock quotes, charts, profile

Quaint Oak Bancorp Inc Income Statement, Balance sheets, Cash Flow Statement

EPS Drops due to Weak Sales at the company over the most recent fiscal period

In the most recent fiscal period Computer Hardware company reported soft top and bottom-line, where reached 0 and revenue by -15.427 % year on year. Revenue were to $5.17 millions in contrast to $6.11 millions eps at $0.00 compared to $0.09 in the corresponding interval a year before.

Socket Mobile Inc Customers

Socket Mobile Inc Suppliers

Better Therapeutics Inc created some good story for the stock market, posting an important growth in most recent fiscal period with operating loss of $-8.322 millions

The Medical Equipment & Supplies sector insiders continue to interpret the fourth quarter of 2022 earnings. Today they monitor operating loss of $-8.322 millions, from the Better Therapeutics Inc , which hasn't specified any revenue thus far, for the respective October to December 31 2022 reporting period.

Better Therapeutics Inc stock quotes, charts, profile

Better Therapeutics Inc Revenue elevation Rates

For the financial fourth quarter of 2022 Aptevo Therapeutics Inc decreased a loss per share of $-0.84 per share compare to $-1.28 a year prior and EPS improved from $-1.50 per share from the previous reporting season.

Revenues remained unscathed to $0.00 millions from $3.67 millions in the same reporting season a year prior and sequentially Revenues surged from $0.00 millions.

Aptevo Therapeutics Inc stock quotes, charts, profile

Aptevo Therapeutics Inc Revenue rise Rates

Underlining the most recent fiscal period Candel Therapeutics Inc Losses have widen at $-0.15 per share, relative to the results of $1.54 per share a year before quarter, In the preceding quarter the Biotechnology & Pharmaceuticals company realized $-0.30 per share.

Candel Therapeutics Inc Suppliers

Candel Therapeutics Inc Income Statement, Balance sheets, Cash Flow Statement

In the most recent fiscal period DBV reached 0 at $0.00 per share, opposite of $0.00 per share a year prior reporting season, In the previous reporting season The company realized $0.00 per share.

Invesco Db G10 Currency Harvest Fund Suppliers

Invesco Db G10 Currency Harvest Fund Revenue growth Rates